Prompt recognition of direct and indirect neurologic complications of systemic cancers and their evolving treatments is essential to maximize favorable outcomes. Neurologists should be familiar with common and rare neurologic toxicities of conventional chemotherapy, immune checkpoint inhibitors, and CAR T-cell therapy.
Amy A. Pruitt (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: